Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 0.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 214,906 shares of the company’s stock after purchasing an additional 1,307 shares during the period. Charles Schwab Investment Management Inc. owned 0.43% of Mineralys Therapeutics worth $2,645,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of MLYS. FMR LLC lifted its stake in shares of Mineralys Therapeutics by 12.0% during the third quarter. FMR LLC now owns 303,758 shares of the company’s stock valued at $3,679,000 after buying an additional 32,663 shares during the period. Martingale Asset Management L P acquired a new position in Mineralys Therapeutics in the 3rd quarter valued at $181,000. Verition Fund Management LLC lifted its stake in shares of Mineralys Therapeutics by 30.6% during the 3rd quarter. Verition Fund Management LLC now owns 27,361 shares of the company’s stock worth $331,000 after purchasing an additional 6,408 shares during the period. PDT Partners LLC acquired a new stake in shares of Mineralys Therapeutics during the third quarter worth $148,000. Finally, Caligan Partners LP boosted its holdings in shares of Mineralys Therapeutics by 31.6% during the third quarter. Caligan Partners LP now owns 981,155 shares of the company’s stock worth $11,882,000 after purchasing an additional 235,397 shares during the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on MLYS. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research report on Monday, March 10th. The Goldman Sachs Group dropped their price objective on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, Guggenheim reissued a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th.

Mineralys Therapeutics Stock Down 7.1 %

MLYS stock opened at $15.00 on Friday. The company has a market cap of $941.78 million, a price-to-earnings ratio of -4.12 and a beta of 1.50. The business has a fifty day simple moving average of $11.38 and a 200-day simple moving average of $12.18. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. As a group, analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. purchased 1,296,296 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average cost of $13.50 per share, for a total transaction of $17,499,996.00. Following the acquisition, the director now owns 4,280,051 shares in the company, valued at approximately $57,780,688.50. This trade represents a 43.45 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Samsara Biocapital Gp, Llc acquired 600,000 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was bought at an average cost of $13.50 per share, for a total transaction of $8,100,000.00. Following the completion of the transaction, the insider now directly owns 5,674,916 shares of the company’s stock, valued at $76,611,366. This trade represents a 11.82 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.